Abstract: Initiation, progression, and completion of the cell cycle are regulated by various cyclin-dependent kinases (CDKs), which are thus critical for cell growth. Tumour development is closely associated with genetic alteration and deregulation of CDKs and their regulators, suggesting that inhibitors of CDKs may be useful anticancer therapeutics. Indeed, early results suggest that transformed and normal cells differ in their requirement for e.g. cyclin/CDK2 and that it may be possible to develop novel antineoplastic agents devoid of the general host toxicity observed with conventional cystostatic drugs. Numerous active-site inhibitors of CDKs have been studied; the main limitation with these ATP antagonists is kinase specificity for CDKs. However, screening of compound collections, as well as rational design based on enzyme-ligand complex crystal structures, are now yielding pre-clinical candidates, particularly certain purine and flavonoid analogues, with impressive potency and selectivity. Natural CDK inhibitors (CKIs), e.g. the tumour suppressor gene products p16 INK4 , p21 WAF1 , and p27 KIP1 , form the starting point for the design of mechanism-based CDK inhibitors. A number of these small proteins have been dissected and inhibitory lead peptides amenable to peptidomimetic development have been identified. Conversion of these peptides into pharmaceutically useful molecules is greatly aided by the recent elucidation of CKI/CDK crystal and solution structures. Additional interaction sites on CDKs being exploited for the purposes of inhibitor design include: phosphorylation/dephosphorylation sites, macromolecular substrate binding site, CKS regulatory subunit binding sites, cyclin-binding site, cellular localisation domain, and destruction box. Finally, progress has recently been made in the application of antisense technology in order to target CDK activity.
INTRODUCTION

CDK DIVERSITY
The topic of CDK inhibition and cancer therapy has been reviewed several times, most recently by Garrett and Fattaey [1] , Walker [2] , and Meijer & Kim [3] . Significant advances have been made in the field since these last overviews, including a better understanding of the pharmacological consequences of inhibiting cell-cycle regulatory CDKs, the discovery of several new classes of small-molecule CDK inhibitors, as well as the solution of important crystal structures of CDKs in complex with various regulatory proteins and chemical inhibitors. The latter topic was reviewed recently [4] . The present review aims to cover in some depth the medicinal chemistry of both inhibitors of the enzymatic function of CDKs, as well as inhibitors of the various protein-protein interactions leading to inactivation of CDK function.
To date nine different CDKs and at least 16 different cyclins in mammalian cells have been described. As can be seen from Table 1 , not all CDKs and cyclins function in cell cycle regulation. In this review only the major CDK/cyclin pairs involved in the regulation of the cell cycle will be considered. CDKs consist of a single polypeptide chain with ca. 200 amino acid residues and contain a catalytic core that is completely inactive when the CDK is not phosphorylated and complexed with a cyclin partner. CDKs are held in an inactive state by at least two major structural constraints: the substrate binding site is blocked and the ATP binding site is distorted in such a way that the ATP phosphates are poorly positioned for efficient phospho-transfer [5] . The conformational changes taking place upon phosphorylation and cyclin binding are now starting to become clear [6, 7] . Until recently the majority of CDK inhibitors have been designed and screened against CDK1 and CDK2 complexes with cyclin A. This probably reflects the comparatively ready availability of these proteins and the fact that of all CDK/cyclin pairs the CDK2/cyclin A system is best understood at the molecular level. However, the CDK/cyclin pairs regulating cell cycle events preceding S phase would seem equally interesting targets for inhibitor design. Recent progress in purification and characterisation of e.g. CDK4/cyclin D1 and CDK7/cyclin H now make it possible to design more readily inhibitors specifically against these targets [9, 10] .
CDKs to specific substrates or sub-cellular locations; their function is primarily controlled by changes in cyclin levels, which increase characteristically at specific cell cycle stages. In addition to cyclin binding, complete CDK activation requires phosphorylation at conserved Thr residues (e.g. Thr 160 in CDK2) located in the so-called Tloop. In vertebrate cell cycle control it appears that a single CDK-activating kinase (CAK) can phosphorylate and thus activate all the major CDK/cyclin substrates. CAK activity is due to the p40 MO15 /cyclin H/MAT1 complex. CAK itself, like its substrates, is a CDK, and p40 MO15 has therefore been renamed CDK7 [10] . At first glance, CDK7, due to its role in activating all of the cell cycle CDK/cyclin complexes, would appear to offer a particularly attractive target for inhibitor design. However, it has to be remembered that CAK activity does not appear to change during the cell cycle and that the stimulation of CDK phosphorylation probably reflects cyclin binding rather than CAK activity [5] . CAK activity is thus not rate limiting during cell proliferation, although its regulation, which is as yet poorly understood, may be important under certain growth conditions [10] .
THE CELL CYCLE
Activation of CDKs
The transitions between the phases of the eukaryotic cell cycle, summarised in Fig. (1) , are regulated at checkpoints, including the restriction point late in the G 1 phase, at which a cell commits itself to another round of DNA replication, as well as the initiation and the completion of DNA replication (S phase) and of cell division (mitosis). Entry into and progression through the cell cycle are triggered by CDKs. In order to assure the are controlled by growth factors. They associate with CDK4 and CDK6, whose primary substrate is the retinoblastoma tumour suppressor protein (pRb) [12] . It plays a critical role in regulating G 1 progression through binding and regulating a large number of cellular proteins, including members of the E2F family of transcription factors. These in turn regulate the expression of many genes, which encode proteins involved in cell cycle progression and DNA synthesis. Binding of pRb to E2F factors inhibits the latter's transcriptional activation capacity and converts them from transcriptional activators to repressors [8] . Phosphorylation of pRb by D-type CDKs results in dissociation of pRb from E2F and expression of the E2F-regulated genes. In cells lacking pRb, D-type CDK activity is not required for cell cycle progression [13] . Through activation of E2F, cyclin E is the next cyclin to be induced. It associates with CDK2 and the resulting complex is important for the G 1 -S transition by maintaining pRb in its hyperphosphorylated form. Unlike the D-type cyclins, cyclin E-type CDK activity is still required in cells lacking pRb, suggesting the existence of other important substrates for CDK2/cyclin E [14] . Like most CDK/cyclin complexes, CDK2/cyclin E also phosphorylates histone H1, an activity probably important for the chromatin rearrangement necessary for replication. Cyclin A accumulates at the G 1 -S transition and persists through S phase. Initially it associates with CDK2, later with CDK1. These CDKs are thus required for entry into S phase, completion of S phase, and entry into mitosis. During the second gap phase G 2 , the cell prepares for the process of division. Mitosis then is regulated by CDK1 in association with cyclins A, B1, and B2. These complexes phosphorylate proteins such as lamins, histone H1, and components of the mitotic spindle. Cyclins A and B must be degraded for a cell to exit mitosis and CDK1/cyclin B activity is involved in the regulation of this destruction process. [36] . q) Ref. [37, 38] . r) Ref. [38] . s) Ref. [39, 38] . t) [ATP] = 375 µM.
CDK Inhibition
The different classes of small-molecule compounds possessing CDK inhibitory activity by virtue of ATP antagonism are discussed in detail below. A summary of the biological activity for the more important representatives, both in terms of biochemical kinase inhibition potency and selectivity, as well as effect on in vitro cell proliferation, is presented in Table 2 . The cytotoxicity data is given, where available, in the format used by the National Cancer Institute (NCI), using the human cancer cell line screen [18] . It should be noted that kinase assay IC 50 An attempt has been made to collect relevant comparable information in a database project but unfortunately this has not as yet progressed to a useful stage [19] .
Biological CDK inhibition can be achieved in many different ways, e.g. indirectly but very importantly through the changes in the levels of the various cyclins during the cell cycle. Direct inhibition by phosphorylation at Thr 14 and/or Tyr 15 in human CDK1 and CDK2 is due to the WEE1/MYT1-related kinases [15] . This inhibition mechanism is particularly important for CDK1 regulation at mitosis. CDK1/cyclin B complexes are kept inactive until Thr 14 /Tyr 15 -dephosphorylation by the dual specificity phosphatase CDC25 at the end of G 2 activates CDK1. Finally, dephosphorylation of Thr 160/161 represents an additional inactivation mechanism, the biological relevance of which remains unclear.
Tumour suppressor functions are provided by the so-called cyclin-dependent kinase inhibitors (CKIs). These are small proteins and fall into two classes: p21 KIP1/CIP1 and p27 KIP1 are specific for CDK2/CDK4 complexes, whereas the INK4 proteins are specific for CDK4/6-cyclin complexes. The CKIs are capable of inhibiting directly the enzymatic activity of CDKs or through interaction with the kinase substrate binding site. The main regulatory mechanisms for the CKIs are transcriptional or responses to mitogens and growth factors. E.g. p21 KIP1/CIP1 is transcriptionally induced by p53, which in turn is a transcriptional regulator mediating cell-cycle arrest in response to DNA damage and in senescense. For p27 KIP1 , regulation by growth factors appears to be important. The CKIs will be discussed in more detail below in connection with peptide and peptidomimetic CDK inhibitors derived from them.
Staurosporins
Staurosporin, a microbial alkaloid, was first isolated from Streptomyces sp. strain AM-2282 (now classified as a new species with the name Streptomyces staurosporeus) and was reported to possess anti-microbial properties against both The ATP binding site is a very common motif present in a host of proteins, including the ca. 2,000 kinases encoded in the mammalian genome. For this reason it has been thought that the development of kinase-specific ATP antagonists devoid of severe toxic effects would be very difficult. However, recent advances in rational drug design and tumour pharmacology suggest that novel cancer therapeutics based on CDK inhibition will be available in the not-too-distant future. At present the first two agents, flavopiridol and CGP60474 (see below), falling within the class of CDK-specific ATP antagonists, are undergoing early clinical evaluation [16, 17] . yeasts and fungi [40] . The compound contains an oxadiazepine skeleton with a fused sugar moiety and possesses the absolute configuration shown in Fig. (2) . instructive in terms of hints for the design of novel CDK inhibitors (see below).
Butyrolactone-I
The isolation from microbial fermentations of further analogues, differing from staurosporin only in that they contain an additional hydroxyl function at C 7 , was reported later [41] . These 7-hydroxystaurosporins are known as UCN-01 and UCN-02 and they are C 7 diastereomers. Unlike staurosporin, these compounds had no antimicrobial properties but they displayed cytotoxic effects on certain mammalian cell lines, UCN-01 being about twice as potent as UCN-02. These cytotoxic effects were hypothesised to emanate from cell growth disturbance through inhibition of protein kinases [41] .
This compound was identified as a CDK inhibitor in the course of a screen of microorganisms. It was found that Aspergillus strain F-25799 produced strong inhibitory activity in an assay against murine cyclin B/CDK1. The active component was subsequently isolated from the mycelia and purified [27] . It turned out to be identical to a compound previously named butyrolactone-I (3.3), first isolated as a new metabolite from Aspergillus terreus var. africanus IFO8835 [44] . Its biosynthesis in this organism has been elucidated [45] and involves conversion of phenylalanine or tyrosine to methyl phydroxyphenylpyruvate 3.1, two molecules of which are then condensed between positions 2 and 3'. The product 3.2 is lactonised, followed by isoprenylation in the last step, see Fig. (3) .
It is now clear that both staurosporin and UCN-01 are indeed potent inhibitors of a wide variety of kinases, including both Ser/Thr-, as well as Tyr kinases. The fact that at least part of the compounds' biological properties may be due to CDK inhibition was shown for both staurosporin [22] and UCN-01 [23] . However, one report suggested that inappropriate CDK activation either correlated with or actually mediated cell growth inhibition with apoptosis in T lymphoblasts exposed to UCN-01 [42] . Interestingly, whereas staurosporin inhibits CDK4/cyclin D1 comparatively poorly [25] , UCN-01 appears to be a potent CDK4 inhibitor [23] .
As far as can be ascertained, no derivatives or analogues of butyrolactone-I possessing CDKinhibitory properties have been reported. The elegant synthesis method used by nature suggests, however, that the substituted butyrolactone represents a good analogue template amenable to chemical synthesis.
Butyrolactone-I appears to be a kinase inhibitor with high selectivity towards CDK1 and CDK2, with little activity on other kinases. In vitro growth of p53-negative pancreatic tumour cells was inhibited by butyrolactone-I with IC 50 values of 94 µM (PANC-1 cell line) and 138 µM (AsPC-1 cell line), respectively [46] . Furthermore, consistent
The structural complexity of the staurosporin molecules does not present a suitable template for the synthesis of analogues with differing selectivity. Nevertheless, the staurosporin/CDK2 complex crystal structure [43] with the proposed CDK-inhibitory mechanism for the compounds, pRb phosphorylation and cyclin A expression were significantly inhibited in treated cells. The fact that apoptotic cell death was observed suggests that exogenous inhibition of CDK1 and/or CDK2 causes restraint of cell proliferation by induction of programmed cell death. A study using various human prostate carcinoma cell lines [47] , on the other hand, revealed inhibition of cell proliferation and incomplete cell cycle arrest in G 2 /M, which allowed for occasional skipping of mitosis and subsequent progression through the cell cycle.
involved in the anti-cancer mechanism of 9-hydroxyellipticine [24] .
The nucleoside antibiotic sangivamycin has been known for some time to inhibit protein kinases A and C and to possess potent anti-proliferative properties [49] . In the course of a screen of culture media from soil microorganisms against CDK1, a potent inhibitor was isolated from Streptomyces sp. LPL931 culture medium. This compound was shown to inhibit CDK1 with a K i value of 1.55 µM, as well as CDK2 with similar potency and was identified as toyocamycin [50] . Toyocamycin is structurally related to sangivamycin, differing only in a nitrile instead of carboxamide substituent on the pyrrolopyrimidine ring as shown in Fig. (4) . Both compounds inhibit e.g. protein kinase C with IC 50 values of 12 µM (sangivamycin) and 90 µM (toyocamycin) [51] . These data suggest that toyocamycin is a CDK-selective ATP antagonist. Furthermore, certain toyocamycin analogues have recently been reported to inhibit CDK1 at low nanomolar concentrations, as well as to cause G 1 and G 2 /M cell cycle arrest, and to induce apoptosis in A549 human lung carcinoma cells [52] . However, the impressive anti-proliferative effects of sangivamycin, toyocamycin, as well as numerous analogues [53, 51] may only partly correlate with inhibition of kinases in general and CDKs in particular, since nucleoside antibiotics possessing furanose groups are phosphorylated in living cells, leading to interaction with additional cellular targets [54] . Nevertheless, toyocamyin-
Other non-Specific CDK Inhibitors
Suramin, a polysulphonylnaphthylurea, has been in use not only as an anti-tumour agent, but also for anti-helminthic and anti-protozoal indications [2] . Suramin appears to interact with numerous intra-and extracellular targets, including CDKs. Thus it was demonstrated that CDK1 is inhibited by suramin with an IC 50 value of ca. 4 µM [26] . It remains unclear to what extent CDK inhibition contributes to the anti-proliferative effects of suramin. 9-Hydroxyellipticine, an indolic alkaloid, represents a similar case. This molecule, and ellipticines in general, are known to exert their anti-proliferative effects through interactions with DNA and/or topoisomerase II [48] . However, it has been suggested that inhibition of pRb phosphorylation via CDK2 inhibition may be Table 2 ).
Flavonoids
Flavonoids play an important role in plant physiology and their interactions with human metabolism are numerous, since they form part of our diet. They are believed to possess properties capable of potential protection against carcinogenesis [57] and have long been known to interact with various kinases at the ATP-binding site [58] . Flavone acetic acid, genistein, and quercetin, whose structures are presented in Fig. The isolation from the stem bark of Dysoxylum binectariferum and the total synthesis of a compound [60] previously described as rohitukine [61, 62] , enabled the synthesis of flavopiridol and its analogues [38] , summarised in Fig. (6) . The main problem in the synthesis of flavones 6.9 concerns the installation of the cis-alcohol function in the piperidine ring. Trimethoxyphenyltetrahydrosubstitutions of OH-modified derivatives of 6.2 with various oxygen nucleophiles do not give 6.7; instead, ring contraction to 6.6 is observed. Similarly, attempted inversion via Mitsunobu reaction failed and resulted only in elimination and reversion to 6.1. For this reason, a rather clumsy route had to be followed, involving conversion to ketone 6.3, followed by borohydride reduction to 6.4. Even here stereoselectivity is poor and the geometric isomers had to be separated through fractional crystallisation or chromatography. The levorotatory enantiomer with the absolute stereochemistry shown for 6.7 is accessible through crystallisation of diastereomeric tartrate salts. Partial demethylation and simultaneous acetylation then provide 6.8, which upon deprotonation and reaction with benzoate esters pyridine 6.1 is readily obtained by Friedel-Crafts acylation of trimethoxybenzene with 1-methyl-4-piperidinone. In principle, epoxidation of the alkene should provide 6.5, which could be reduced directly to the (racemic) cis-arylpiperidinol 6.7. Unfortunately, epoxide 6.5 does not appear to be accessible from 6.1 using peracids. The fact that the reaction also fails with various salt forms of 6.1 indicates that not only interference through Noxidation is involved. Hydroboration/oxidation of alkene 6.1 is possible but affords the transarylpiperidinol 6.2, as expected from the mechanism of this reaction. appearance of apoptotic cells in xenografted head and neck squamous cell carcinomas have been reported [65] . The promising preclinical effects seen with flavopiridol [38] have led to phase I/II clinical evaluation of the drug. Initial results are encouraging in that the drug was comparatively well tolerated, concentrations needed for CDK inhibition in preclinical models could be achieved safely, and some antineoplastic effects were observed [16] .
Around 100 rohitukine derivatives were tested for EGF-receptor tyrosine kinase inhibitory activity [38] . It was found that the enzyme-and the in vitro anti-tumour SARs correlated well and that flavopiridol was the most potent compound. Subsequent studies revealed that flavopiridol inhibited CDKs approximately 100-fold more potently than tyrosine kinases. This observation, together with mechanistic studies, lead to the conclusion that CDK inhibition was more relevant to flavopiridol's cell growth inhibition properties than EGF-receptor tyrosine kinase inhibition. In fact the SARs for the inhibition of these two enzymes by rohitukine analogues overlap at least in part. Most relevant to CDK2 inhibition are the following structural correlations: removal of the chlorine substituent on the phenyl group of flavopiridol reduced activity ca. 10-fold; conversely, introduction of chloro substituents at the 4-or 5-position of the same ring also reduced activity. Further loss of activity was seen upon replacing the chlorophenyl group with small aliphatic groups. Replacement of the hydroxy groups at the 5-and 7-positions of the flavone moiety also dramatically reduced inhibitory potency. As far as stereochemistry is concerned, the cis(-) isomer possessed higher potency than either the cis(+) or the trans(+/-) isomers. Certain SARs suggest that selectivity towards individual CDKs can be achieved. Thus it was found that replacement of the chloro substituent by fluoro, bromo, methyl, or hydroxyl groups reduced activity relative to flavopiridol; however, the bromo and fluoro derivatives showed about 2-fold greater selectivity towards CDK2. Replacement of the chlorophenyl group with 2-or 3-pyridyl groups resulted in reduced activity. However, the corresponding 4-pyridyl derivative was equipotent with flavopiridol against CDK2 but significantly less selective for CDK4 and CDK7. Substitution of a pyridyl group for the N-methylpiperidine ring, on the other hand, increased selectivity for CDK4.
Purines
The story of substituted purines as CDK inhibitors begins with 6-dimethylaminopurine, shown in Fig. (7) , first described as an inhibitor of cell division in embryos [66] and later found to be a CDK1 inhibitor [67] . Subsequently, using a new screening test based on starfish CDK1/cyclin B for antimitotic compounds, isopentenyladenine, a nonselective kinase inhibitor with activity against CDK1, was identified [68] . In a systematic study using cytokinin-derived purine analogues, olomoucine was then discovered as the first truly CDK-selective purine [29] . Further SAR studies around 2,6,9-trisubstituted purines lead to the discovery of a closely related compound, roscovitine, with approximately 10-fold increased potency against CDKs and similar selectivity [31, 69] . The purine analogues with the highest CDK inhibitory potencies reported to date are the purvalanols [70] . They were obtained after combinatorial synthesis and screening of several hundred 2,6,9-trisubstituted purines. Purvalanol B is more potent in biochemical CDK assays than purvalanol A; the former compound possesses little activity on cells, however.
Of all the classes of compounds with CDK inhibitory activity, the purines are best understood in terms of their SARs. The order of importance of the three purine ring substituents with respect to kinase inhibition is 2-> 6-> 9-. Furthermore, approximate additivity of the three substituents is observed. Presumably this is due to the fact that the rigid purine scaffold does not permit the 2-, 6-, and 9-substituents to bind in overlapping regions of the active site. The SARs are summarised in Fig. (8) and are discussed in detail below.
In accordance with its proposed biological mechanism as a general CDK inhibitor, flavopiridol was shown to inhibit both CDK2 and CDK4 in vivo and to inhibit cell cycle progression in either the G 1 or G 2 cell cycle phase [63] . Furthermore, significant in vivo anti-tumour effects were observed with xenografted lung, colon, mammary, and ovarian tumours, as well as glioblastomas using daily oral dosing [64] . Similarly, sustained tumour reduction (60 -70 %), as well as
The majority of purine analogues reported possess a 2-substituent containing an hydroxyethylamino or aminoethylamino [71] motif. However, in some analogues with conformationally constrained 2-substituents, the number of carbon atoms separating the two functional groups may be as high as four. In non-cyclic hydroxyalkylamino 2-substituents, a (preferably branched) alkyl group vicinal to the amino function has yielded some of the most potent compounds to date. Certain cyclic hydroxyalkyl and aminoalkyl groups, either vicinal to N 2 or including it, also yield potent compounds. Clearly the amino group bonded to the purine ring can be 2 o or 3 o , also shown by the fact that (dihydroxyethyl)amino 2-substituents provide potent inhibitors [72] . Furthermore, this amino group can be replaced by an alkynyl group, but apparently not by alkenyl or alkyl groups [73] . The crystal structure complexes of CDK2 with olomoucine [74] , roscovitine [75] , and purvalanol B [32] all show that the hydroxy group in the 2-substituent contributes an important H-bond to the active site. Nevertheless, potent compounds containing a thiomorpholine function, the sulphur atom being unable to act as an H-bond donor, have been reported [76] .
substitution patterns on the aromatic ring vary between the anilino-and benzylamino series. In the former, substituents of any kind are poorly tolerated in the ortho position. Activity gains can be made with certain electron-withdrawing substituents in the meta position, particularly chloro and bromo groups. The same is true, although to a much lesser extent, of the para position. Interestingly, amino-and carboxyl-substitution in addition to the meta-chloro group, has yielded the most potent analogues. For purvalanol B, where this additional group is a carboxylic acid, a saltbridge from this group to the Lys 89 side chain in the ATP binding pocket, as well as further additional interactions, can be observed [70] . As pointed out above, addition of such protic substituents, while increasing CDK inhibitory activity, appears to be detrimental to anti-tumour activity, perhaps due to poor cellular uptake of such compounds. In the 6-benzylamino series, addition of further substituents to the aromatic ring does not generally have the same dramatic effects as in the 6-anilino series. However, certain electron-releasing groups in the para-(particularly methoxy), and electronwithdrawing groups in the meta position (notably iodo), correlate with increased potency.
The 6-position of purine analogues with potency and selectivity towards CDKs is invariably substituted by benzyalmino or anilino groups. Unlike in the 2-substituent, the amino group here needs to be 2 o rather than 3 o . CDK2/purine crystal structures show an important hydrogen bond between the purine N 6 H group and the Leu 83 backbone carbonyl of the ATP active site. The best The 9-position of the purines is very restrictive towards substitution in terms of CDK inhibition. Only small aliphatic and alicyclic groups, optionally containing hydroxyl groups [77] , are tolerated. The 9-isopropyl group appears to be optimal. Addition of methyl substituents at N 1 , N 3 , or N 7 of purines dramatically reduces CDK2 inhibitory activity [69] . Little appears to be known about the influence of substituents at C 8 , although this position would appear to be synthetically accessible, particularly using the synthetic route of Legraverend et al. [78] . solution are summarised in Fig (9) . The most convenient starting material is 2,6-dichloropurine (9.2, X = Cl). Due to the pronounced difference in reactivity towards substitution of the chloro substituents in the 2-and 6-positions of the purine ring, selective amination under comparatively mild conditions readily affords aminochloropurines 9.3. The reaction succeeds even with deactivated aryl amine educts R 1 -NH 2 under suitable conditions. Deprotonation of the N 9 H group in 9.3 with either NaH or K 2 CO 3 in polar aprotic solvents, followed by alkylation with alkyl halides R 2 -X cleanly affords the disubstituted intermediates 9.8. Finally, if the desired trisubstituted purine 9.9 has an alkylamino R 3 substituent, as is usually the case, the 2-chloro group is substituted at elevated temperature with excess alkyl amine. If the alkyl amine is a liquid, the sealed tube method is usually favoured, else heating a solution in Nmethylpyrrolidinone or Me 2 SO is adopted. However, poor reactivity of the 2-chloro group in 9.8 precludes this final amination reaction for As far as selectivity within the CDKs is concerned, only minor differences between the various 2,6,9-trisubstituted purines can be discerned. There is one notable exception, however: purvalanol A (as opposed to purvalanol B) is the only purine with submicromolar IC 50 against CDK4. Apart from flavopiridol, this would in fact seem to be the only CDK-selective compound with appreciable activity against CDK4.
The routes commonly used [79, 76, 69, 80, 77] for the synthesis of 2,6,9-trisubstituted purines in many sterically hindered and poorly nucleophilic alkyl-and aryl amines. The 2-fluoro group (9.8, X = F) renders the purine 2-position much more electrophilic and has been found to be more versatile for the final amination step. It is introduced (9.2, X = F) by diazotisation/fluorinocyclised to 9.7 under acid-catalysed conditions using excess triethylorthoformate. Further transformation to 9.4 (X = I) involves diazotisation/substitution of the amino group in 9.7, the iodide source being provided by a mixture of CH 2 I 2 , I 2 and CuI. Similar to the fluoropurines 9.4 (X = F), the iodopurines 9.4 (X = I) are superior to chloropurines 9.4 (X = Cl) for the final amination reactions. Additionally, iodopurines 9.4 (X = I) are suitable if the desired products 9.9 contain alkyl rather than alkylamino R 3 substituents, since they can be used directly in Pdcatalysed cross-coupling reactions with terminal alkynes [73] . In a further synthetic route [82] , regioselective N 9 -alkylation of 9.1 is performed as the first step, followed by Mitsunobu alylation of the product 9.10 with alcohols R 3 -OH. In order to render the 2-amino group in 9.10 sufficiently acidic to undergo Mitsunobu alkylation, it was first acylated with trifluoroacetic anhydride. The trifluoroacetyl group was then removed by basic lysis of 2-amino-6-chloropurine 9.1 [81] . In those cases where the R 1 group contains functions sensitive to alkylation, the order of 6-amination and 9-alkylation can be reversed. Thus 9.2 can be N 9 -alkylated directly using the same conditions as above, although formation of 9.4 is accompanied by N 7 -alkylation. Regioselectivity has been reported [82] to be good if alkylation is carried out using 1 o or 2 o alcohols R 2 -OH under Mitsunobu conditions [83] . A different route to the 9-alkylpurines 9.4 has recently been described [78] . In this case 2,5-diamino-4,6-dichloropyrimidine 9.5 [84] is the starting material, which is selectively C 4 -monosubstituted using one equivalent of R 2 -NH 2 . The product 9.6 is then Fig. (10) . A solid-phase synthesis route for 2,6,9-trisubstituted purines.
hydrolysis prior to purification of the alkylated products 9.11. Since the R 3 group in most target compounds 9.9 itself contains an alcohol function, this requires protection, e.g. as a silyl ether. The final step, i.e. 6-amination of 9.11, was carried out as usual.
followed by alkylation as usual to afford the 9-alkylated products 10.8. These were aminated at the 2-position (refer above) to give the immobilised target compounds 10.9. The remaining step was acidolytic cleavage of the purine-linker bond in order to obtain the free 2,6,9-trisubstituted purines 10.10. The limitations of the approach are that 2 o amines at the 6-position cannot be introduced and that the reactivity of the solid-phase bound fluoropurines 10.8 towards bulky amines R 3 -NH 2 was much lower compared to the corresponding transformations in solution.
Various solid-phase synthesis approaches for the preparation of trisubstituted purines have been developed [81, 70, 82] . The most versatile of these is summarised in Fig. (10) . Amino-functionalised solid-phase synthesis resins 10.1 were acylated with 5-(4-formyl-3,5-dimethoxyphenyloxy)valeric acid 10.2. Resin 10.3 was then transformed with amines R 1 -NH 2 by reductive amination. In order to be able to perform the amination reaction at the 6-position of the purine 10.5 with weakly nucleophilic amines 10.4 (depending on the nature of R 1 ), the overall electrophilicity of the purine system had to be increased. The best solution to this problem was derivatisation of the N 9 position with the trimethylsilylethoxymethyl activating group. Condensation of solid-phase bound 10.4 with the derivative 10.6 did indeed occur under very mild conditions. Product 10.7 was then deprotected with tetrabutylammonium fluoride,
Paullones
Fused [1]benzazepine-2,5-diones were first investigated as anti-tumour agents on the basis that they may represent anti-metabolites of riboflavin and vitamin B 12 , both of which play a role in certain tumours. A number of such compounds, e.g. those with structures 11.1 -11.4 shown in Fig. (11) , were indeed found to possess marked anti-tumour activity. The lack of tumour cell line selectivity observed with e.g. 11.4 suggested a non-specific mode of cytotoxicity, however [85] . 
Indigoids
Chronic myelocytic leukaemia has traditionally been treated in Chinese medicine with a mixture of herbs, one of the active ingredients of which was traced to the dark blue powder prepared from the leaves of a variety of plants [36] . This powder contains a high proportion of the blue dye indigo; however, the anti-leukaemic activity was attributed to the red-coloured isomer of indigo, known as indirubin [90] . The pharmacology of indirubin and some of its analogues, refer Fig. (14) , including 5-halogenoindirubins, N-ethylindirubin, and Indirubin (R 1 = O, R 2 = H) Fig. (14) . Structures of indigoids. indirubin-3'-monoxide is fairly well understood but the fact that indirubins are CDK inhibitors was discovered only recently (Ref. [36] and references cited therein). Indirubin and its analogues selectively inhibit CDKs and block cell proliferation in the late G 1 and G 2 /M phases of the cell cycle.
New Compounds
A series of purine-based CDK inhibitors exemplified by a compound described as O 6 -cyclohexylmethylguanine, see Fig. (16). apparently with inhibitory activity comparable to olomoucine against CDK1, but > 50-fold more active against CDK4, were reported [95] . Crystal structures of selected compounds from this series bound to CDK2 revealed a different binding mode to e.g. olomoucine, with the O 6 -alkyl substituents overlapping the ribose-binding domain of the substrate ATP. Interestingly, removal of the 2-amino group from NU2058 reduced potency against CDK1 but not against CDK2, whilst methylation at N 9 reduced potency against both. Corresponding 4-substituted 5-nitroso-pyrimidines were also shown to be potent CDK inhibitors [96] . Thus NU6027 showed low micromolar activity against CDK1 and CDK2. The relationship of the pyrimidine analogues with the purine analogues is not entirely clear, although alkylation of the 6-amino and replacement of the 5-nitroso groups in the latter correlated with loss of potency.
Although a comparatively large number of indirubin analogues have been reported [91] [92] [93] [94] , kinase inhibition SARs for only indigo and four indirubin derivatives have been published [36] . As is the case with most selective CDK inhibitors, activity against CDK4 was about one order of magnitude less than against the other cell-cycle CDKs for most indirubin analogues, with the exception of indirubin itself, which is approximately equipotent against all CDKs examined but has comparatively poor overall potency. Both 5-chloroindirubin and indirubin-3'-monoxime show high nanomolar IC 50 s against CDK1 and CDK2, whereas indirubin-5-sulphonic acid is even more potent. The latter compound, despite its high inhibitory activity against CDKs, had limited effects on cell proliferation, presumably due its limited permeability.
A different pyrimidine-based compound, termed CGP60474 and representative of a group of compounds described as a phenylamino pyrimidine derivatives [97] , was reported to be a potent and selective CDK inhibitor with specificity for CDK1 and CDK2. The presumed structure of CGP60474 is shown in Fig. (16) [4] . Potent (IC 50 s 10 -100 nM) in vitro anti-proliferative effects against a variety of human tumour cell lines, as well as potent anti-tumour activity agaist various human Indirubins 15.3 are synthetically accessible through condensation between indoxyl derivatives 15.1 and isatins 15.2 [93] as shown in Fig. (15) . The generality of this reaction, together with the fact that both indoxyls and isatins can be synthesised by cyclisation of precursors derived from anthranilic acid, renders the indirubin system interesting for further analogue synthesis and evaluation. tumours transplanted onto nude mice, were reported [98] .
analogues with the general structure 17.2b were reported as CDK inhibitors [101] . Indenopyrazole 17.3a, found by high-throughput screening against CDK4/cyclin D1, formed the starting point for a SAR program which afforded analogue 17.3b, reputedly a potent and selective CDK4 inhibitor, capable of inducing cell cycle arrest and apoptosis in tumour cell lines [102] .
Interesting new compounds, variously found by selective screening against CDKs of compound collections and through structure-based design, have recently been reported. While little is known at present regarding their in vitro and in vivo potencies, selectivities, pharmacokinetics, etc., some examples are shown in Fig. (17) .
A class of sulphonamides possessing antitumour properties due to interference in the progression through the M-phase of the cell cycle was reported and compound E7010, the optimised compound from this class, was shown to be a potent tubulin polymerisation inhibitor. Further synthesis of a large number of sulphonamides revealed that certain N-(7-indolyl)benzenesulphonamides, notably compound E7070, also had antiproliferative properties but that these were not due primarily to antimitotic effects but due to a block in progression through G 1 -phase [103] . Although the main cellular target for compound E7070 has not as yet been identified, it is possible that CDK inhibition may be involved. E7070 is currently undergoing phase I clinical trials in Europe [104] .
The substituted diaminoacylthiazole 17.1a was identified as a CDK inhibitor through library screening. Molecular modelling-assisted SARstudies later identified more potent compounds 17.1b (X = Cl or F), which apparently possess low nM K i s against CDK1/cyclin B, CDK2/cyclin A, and CDK4/cyclin D, as well as showing significant tumour growth delay in mouse tumour xenograft models [99] . Interestingly, the class of compounds exemplified by 17.1a and 17.1b was reported to encompass examples with > 100-fold selectivity for CDK4, as well as examples equipotent against CDK1, CDK2, and CDK4 [100] . Indoline 17.2b was identified through molecular modelling. Starting from this lead, potent 
Insights from Crystal Structures Between CDK2 and ATP Antagonists
A range of structurally diverse molecules have been shown to inhibit CDKs by virtue of being ATP antagonists. Several complex structures of such inhibitors with CDK2 have recently become available and some of these are shown diagramatically in Fig. (19) . The CDK2 portions, with the exception of the positioning of certain active-site residue side chains, in all the known complexes with ATP antagonists are practically identical to that found in the CDK2 apoenzyme [105] , the ATP complex [105, 106] , and are very similar to that in the CDK2/cyclin A complex [107] . The inhibitor portions invariably bind into the deep ATP-binding cleft between the N-and C-terminal lobes of CDK2.
Articulation about the hinge region connecting these two lobes permits a range of possible relative domain orientations in protein kinases. Together with the observed flexibility of the residue side chains within the active site, this goes some way in rationalising why selective inhibitors exist. Furthermore, exploitation of sequence differences between various kinases as shown in Fig. (20) in the residues surrounding the conserved ATPbinding points, as well as novel interactions within the binding cleft, form a useful basis for the design of novel selective inhibitors [108] .
Purines
The purine ring of isopentenyladenine is rotated ca. 180 o with respect to ATP around an axis through the N 3 and N 7 atoms, allowing the isopentenyl group to contact the binding pocket area occupied by the ribose in ATP. In the olomoucine complex, the purine ring is oriented differently: here the hydroxyethyl group of N 2 binds into the ATP ribose pocket, whereas the N 6 benzyl group binds between β-strand 1 and the β5-α2 connecting loop, which bridges the two domains of CDK2 [74] . The purine ring of roscovitine, as well as its substituents, are located in the CDK2 structure in a similar orientation to those of olomoucine [75] . The overall geometry of purvalanol B bound to CDK2 resembles that of both olomoucine and roscovitine [32] . A conserved pair of H-bond interactions between the purine N 7 and the backbone NH of Leu 83 , and between the N 6 amino group and the backbone carbonyl of Leu 83 can be observed in all three (olomoucine, roscovitine, purvalanol B) CDK2/purine complexes. Another conserved Hbond in these complexes is that between the acidic C 8 position of the purine ring and the carbonyl The structures were generated by superimposition of the ATP-binding residues in CDK2 shown in (a). For ATP [106] , staurosporin [43] , and purvalanol B (only the main conformation shown) [32] , the published crystal structure co-ordinates were used, flavonoid L868276 [109] and kenpaullone [110] were modelled. :b  10  20  30  40  50  60  CDK2  MENFQKVEKIGEGTYGVVYKARNKLTG-EVVALKKIR-LDTETEG---VPSTAIREISLLKELN---HPNIV  CDK1  MEDYTKIEKIGEGTYGVVYKGRHKTTG-QVVAMKKIR-LESEEEG---VPSTAIREISLLKELR---HPNIV  CDK4  MATSRYEPVAEIGVGAYGTVYKARDPHSG-HFVALKSVR-VPNGGGGGGGLPISTVREVALLRRLEAFEHPNVV  CDK6  MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVR-VQTGEEG---MPLSTIREVAVLRHLETFEHPNVV  CDK7  MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTN-QIVAIKKIK-LGHRSEAKDGINRTALREIKLLQELS---HPNII  ERK2 MVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNK KLLDVIHT :  140  150  160  170  180  190  CDK2 GAIKLADFGLARAFGVPVR
L1:b1--:L2------:b2----:L3-:b3-----:L4------: a1----------:L5-------
-----ENKLYLVFEFLHQDLKKFMDASALTG--IPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTE CDK1 SLQDVLMQ-----DSRLYLIFEFLSMDLKKYLDS-IPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDK CDK4 RLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPG--LPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSG CDK6 RLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPG--VPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSS CDK7 GLLDAFGH-----KSNISLVFDFMETDLEVIIKD---NSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDEN ERK2 GINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKT---QH--LSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTT KPCa QLHSCFQT-----VDRLYFVMEYVNGGDLMYHIQ--QVG-KFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSE KAPa KLEFSFKD-----NSNLYMVMEYVPGGEMFSHLR--RIG-RFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQ KPBb RLYRTFKD-----SKYLYMLMEACLGGELWTILR--DRG-SFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHR EGFR RLLGICLT-----S-TVQLITQLMPFGCLLDYVREHKDN--IGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTP SRC QLYAVVSE------
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LVCKVADFGLARLIEDNEYT-ARQGAKFPIKWTAPEAALYGR--FTIKSDVWSFGILLTELTTK :: ***:.: : . * *: * . *: Fig. (20) . Sequence alignment of ATP-binding domains of various kinases. ClustalW multiple sequence alignment was performed using the following sequences: CDK2, CDK2-human cell division protein kinase 2, sp|P24941|; CDK1, CC2-human cell division control protein 2 homolog, sp|P06493|; CDK4, CDK4-human cell division protein kinase 4 (EC 2.7.1.-) sp|P11802|; CDK6, CDK6-human cell division protein kinase, sp|Q00534|; CDK7, CDK7-human cell division protein kinase 7, sp|P50613|; ERK2, ERK2-human extracellular signal-regulated kinase 2, (mitogen-activated protein kinase 2), sp|P28482|; KPCa, KPCA-human protein kinase C, alpha type, sp|P17252|; KAPa, KAPA-human cAMP-dependent protein kinase, alphacatalytic subunit, sp|P17612|; KPBb, KGPB-human cGMP-dependent protein kinase, beta isozyme, sp|P14619|; EGFR, EGFR-human epidermal growth factor receptor precursor, sp|P00533|; SRC, SRC-human proto-oncogene tyrosine-protein kinase SRC (P60-SRC) (C-SRC), sp|P12931|. Sequence positions known to be involved in ATP interactions in the case of CDK2 are shaded [106] . The secondary structure designations refer to CDK2, as well.
oxygen of Glu 81 . Consistent with the SAR seen for N 9 substituents in the purine analogues, this group packs into a small hydrophobic pocket involving Val 18 , Ala 31 , Phe 80 , Leu 134 , and Ala 144 . As is the case for olomoucine and roscovitine, purvalanol B's C 2 side chain is bound in the ATP ribose binding pocket, although its precise position is different: the R-isopropyl group makes numerous hydrophobic contacts with the Gly-rich L2 loop of CDK2 and the hydroxyl forms an H-bond to the backbone carbonyl of Gln 131 . This results in an open pocket in the active site lined by polar side chains of Lys 33 , Asn 132 , and Asp 145 . Since this region in the flavonoid/CDK2 structure is occupied by the N-methylpiperidine ring [109] , it has been speculated that further increases in affinity of the purvalanols may result from appending additional substituents at the C 2 position [70] . In all three purine/CDK2 complexes, the aromatic groups on N 6 bind in a region outside the conserved ATP binding site. This region is also occupied by the phenyl group in the flavonoid/CDK2 complex. The interactions in question are hydrophobic in nature and involve mostly His 84 , Phe 82 , Lys 89 , Glu 8 , and Ile 10 in CDK2. It is thought that interactions in this region may be responsible for the increased CDK selectivity of certain purines and flavonoids. In the staurosporin/CDK2 complex structure the C1-containing phenyl ring binds in this region. However, it does not extend out of the cleft as far as e.g. the olomoucine N 6 benzyl ring and does not make any comparable significant contacts except a van der Waal's interaction with Ile 10 [43] . An additional interaction between the chloro group and the side chain of Asp 86 is observed in the case of purvalanol B. Two different orientations observed, involving ca. 160 o flipping of the chlorophenyl ring, suggest a partially protonated state of Asp 86 .
Numerous para-substituents in the N 6 -anilino purine series are tolerated; this is consistent with the solvent accessibility of that site and may provide an opportunity for the fine-tuning of the inhibitor's physico-chemical properties.
ATP-binding cleft more fully than either ATP or staurosporin. Although not precisely mimicking the ATP α-phosphate group, the sulphonate group in indirubin-5-sulphonic acid also interacts with the side chain of Lys 33 . Furthermore, the sulphonate oxygen contacts the backbones of Asn 132 and Asp 145 . The monoxime group of indirubin-3'-monoxime occupies the ATP ribose-binding site and makes no direct interactions with CDK2.
Staurosporin
This large hydrophobic kinase inhibitor becomes mostly solvent inaccessible when bound to CDK2 [43] . Again the familiar H-bonds to Glu 81 and from Leu 83 are observed, as well as numerous hydrophobic contacts. As pointed out above, lack of significant interactions of staurosporin with the hinge loops L2 and L7 may account for its promiscuity with respect to kinase inhibition. The main difference between the CDK2 complexes with staurosporin on the one hand and ATP/other inhibitors on the other hand appears to be the amount of apolar surface area buried. Thus formation of the CDK2/staurosporin complex buries 545 Å 2 apolar surface (274 Å 2 contributed by CDK2, 272 Å 2 by staurosporin), compared with 265 Å 2 apolar surface buried in the ATP/CDK2 complex (175 Å 2 contributed by CDK2, 90 Å 2 by ATP). The staurosporin/CDK2 shows that only carbon atoms 1 -3, 22, 24, & 26 of staurosporin retain any accessible surface area and that this is appreciable (16 Å 2 ) only for C 1 . The possibilities to design derivatives of staurosporin with altered specificity would therefore seem limited.
Flavonoids
The differences in the binding modes of closely related purines is mirrored in the flavonoid situation, where myrecetin apparently binds in the ATP binding site of CDK2 in a reverse orientation compared to flavopiridol [2] . The benzopyran ring of L86-8276 occupies about the same region as the purine ring of ATP. The two rings overlap in the same plane in such a way that the carbonyl O 4 and hydroxyl O 5 are close to the positions of the N 6 and N 1 atoms of the ATP adenine ring. These two oxygens are involved in H-bonds with Phe 82 /Leu 83 and Glu 81 , respectively. Two of these residues are also involved in H-bonding to the purine rings in olomoucine, roscovitine, and purvalanol B. Numerous hydrophobic interactions between the benzopyran ring and CDK2 (mainly Ile 10 and Leu 134 ) are also observed. The positions of the Nmethylpiperidine and phenyl rings were discussed above in relation to the purines. The flavopiridol molecule currently in clinical trials has a chlorophenyl in place of the phenyl group in L86-8276. This modification increases kinase inhibition by a factor of around 7. This is probably due to new possible contacts between the chlorine and residues Ile 10 , Phe 82 , and Leu 83 .
Apart from almost completely non-selective kinase inhibitors, flavopiridol appears so far to be the only CDK-specific ATP-antagonist with high inhibitory activity against CDK4 and CDK6. To date no compounds have been reported with unique selectivity for CDK4/6, although Garrett and Fattaey [1] claim to have found such an inhibitor by high-throughput screening of a large chemical library; unfortunately neither chemical structure nor any other details were given. Although flavopiridol's CDK4/6-selectivity may well be significant for its superior anti-tumour effects, this selectivity is difficult to rationalise on the basis of available structural information. Presumably this question will not be answered until a highresolution crystal structure of CDK4 or CDK6 in complex with an appropriate inhibitor has been solved.
Indigoids
Both indirubin 3'-monoxime and indirubin-5-sulphonic acid have been co-crystallised with CDK2 [36] . Like other small-molecule CDK inhibitors, they bind at the ATP binding site. The familiar H-bonds involving the backbone carbonyl of Glu 81 , as well as both the backbone NH and carbonyl of Leu 83 , are seen in these structures as well, here the bonding partners are the lactam nitrogen, lactam oxygen, and the indole nitrogen, respectively. Both indigoids fill the back of the The fact that the receptor affinity, and hence the potency, of ATP antagonists can potentially be improved with the aid of structure-based design of novel antagonists is indicated by the following: ATP itself has comparatively poor affinity for the catalytic site of CDKs; the ATP binding pocket is not fully occupied by ATP or any of the known inhibitors, apart from the non-selective kinase inhibitor staurosporin. From the relevant complex crystal structures it has been estimated that ATP, olomoucine, flavopiridol, and purvalanol B occupy ca. 78, 76, 74 , and 86 %, respectively [82] .
While both cyclin D -CDK4/6 and cyclin A/E -CDK2 kinases phosphorylate pRb, their macromolecular substrate specificity and preferred phosphorylation sites appear to be different. CDK4/6 preferentially phosphorylate Ser 780 of pRb in a cell-cycle-dependent manner, leading to the inability of pRb to associate with E2F transcription factors [113] . 
INK4 CKIs
The 156 amino-acid residue protein p16 INK4a was first identified and demonstrated to be a specific inhibitor of the CDK4/cyclin D kinases in 1993. [111] . Inhibition of cell cycle progression through the G 1 phase by this protein was found to be associated with suppression of phosphorylation of the CDK4 and CDK6 substrate pRb [112] . Fig. (21) . The high-resolution (1.9 Å) crystal stucture complex between p19 INK4d and CDK6 [118] is depicted. The secondary structure of p19 INK4d is shown in green, that of CDK6 in blue. Residues of p19 INK4d which make contacts with CDK6 are coloured white. In the CDK6 structure, the PLSTIRE helix is coloured light-blue, key residues of the catalytic cleft are shown with side chains (red). The catalytic triad (Lys 43 , Glu 61 , and Asp 163 ) is shown in yellow, the T loop in violet.
appear to be functionally redundant, however, as their transcription seems to be regulated differentially, e.g. during senescence and in response to oncogenic stimuli (p16 INK4a ), in response to the growth-inhibitory factor TGFβ (p15 INK4b ), and particularly during S-phase. The INK4 proteins contain four to five consecutive ankyrin repeats (motifs particularly associated with protein-protein interactions [115] ) stacked linearly as helix bundles and consisting of a helix-turn-helix motif, successive repeats being linked by β-structures. The structure of p16 INK4a has been found to be both thermodynamically and kinetically unstable, rendering the protein vulnerable to singlepoint mutations. This vulnerability provides one explanation for the striking frequency of tumourassociated p16 INK4a mutations [116] .
cyclin binding site, refer to Fig. (21) . The binding of cyclins to CDK4 or CDK6 is thus prevented indirectly through allosteric changes induced by INK4 CKI binding. These changes cause the Nand C-lobes of the kinase to twist away from each another, leading to a misalignment of these lobes, as well the PLSTIRE helix (PSTAIRE in CDK2) and the T loop. While both INK4 CKIs and cyclins need to interact with both lobes of the CDK for their biological function, they require them in different relative orientations [7] . Whenever INK4 CKIs are present in vivo, they appear to dominate over the cyclins with respect to the interaction with CDK4/6. Additionally, the binding of INK4 CKIs to CDK4 or CDK6 appears to lead to distortion of the ATP-binding site. Portions of the catalytic cleft which normally make contact with ATP are dislodged upon CKI binding in such a way as to suggest a significant decrease in the affinity of the kinases for ATP and to disorient severely bound ATP with respect to catalysis. This fact, together with the finding that INK4 CKIs do not directly
The structures of CDK6 bound to p16 INK4a [117] and the closely related p19 INK4d [118] CKIs show that the INK4 inhibitors bind next to the ATPbinding site of the catalytic cleft, opposite to the Fig. (22) . Interface between p16 INK4a and CDK6.The illustration was constructed from the complex crystal structure [117] . 
KIP/CIP CKIs
Members of the KIP/CIP family of tumour suppressor proteins, which includes p27 KIP1 , p21 CIP1/WAF1 and p53 KIP2 [125, 126] , contain a 65-residue region with 38 -44 % homology (refer to Fig. (23) ) in their N-terminus which is necessary and sufficient to bind to and to inhibit cyclin/CDK complexes with broad specificity for the G 1 and S phase kinases over the mitotic ones. The function of these cyclin-binding domains in CKIs and other proteins will be discussed in more detail below. Their C-terminal domains vary in length, sequence, and function [127] . Furthermore, they can bind cyclins and CDKs independently, but they have higher affinity for the preformed cyclin/CDK complexes. The only crystal structure available of a KIP/CIP CKI in complex with a CDK/cyclin is that of an N-terminal fragment of p27 KIP1 and CDK2/cyclin A [128] . The fact that p27 KIP1 binds to both the CDK and cyclin partner is depicted in Fig (24) .
Prior to elucidation of the INK4 CKI/CDK6 complex crystal structures a systematic study [119] using overlapping 20mer synthetic peptides spanning the entire sequence of p16 INK4a suggested that residues 84 -103 were directly involved in CDK4/6 binding. Furthermore, the peptide subtending these residues was found to be capable of inhibiting pRb phsophorylation in vitro. Moreover, a linear construct of this peptide with the cellular delivery vector derived form the Drosophila antennapedia homeodomain (residues 43 -58) [120] mediated the same effect in vivo, as well as blocking cell-cycle progression into S phase through a pronounced G 1 arrest. It is worth noting that an independent study observed similar effects with a recombinant form of the full-length p16 INK4a protein fused to the same antennapedia peptide [121] . Further optimisation of the p16 INK4a (84 -103) peptide [122] identified residues 90 -97 as being particularly important to the peptide's biological function. These findings correlate well with the mechanism proposed for CDK4/6 inhibition by INK4 CKIs summarised in Fig. (22) , which suggests a prominent role for residues in the α5 and α6 helices, as well as loop 6 of the CKIs (in particular Asp 84 , Arg 87 , Phe 90 , and Asp 92 ). Structural and functional analysis of a number of site-specifically mutated p16 INK4a analogues also stressed the importance of the third helix-turn-helix motif (mutants F90A, V95A, V96A, and R99A) [123] . In terms of peptide mimetics of p16 INK4a it can be imagined that the hydrogen-bond interactions from Asp 84 /Arg 87 and Asp 92 to CDK4/6 may serve as initial binding points leading to positioning of the Phe 90 side chain, which plays a central role in the dislocation of the ATP-interacting loop in the catalytic cleft.
The obvious way in which p27 KIP1 inhibits CDK2 is by insertion of a small 3 10 -helix into the catalytic cleft. The details of this interaction are shown in Fig. (25) . A tyrosine side chain of p27 KIP1 , conserved amongst all CIP proteins (boxed residue in Fig. (23) ), mimics the apolar contacts made by the ATP purine ring, as well as the H-bonds made by N 1 and N 6 of ATP. At the Cterminus of the helix, backbone carbonyl groups form H-bonds to an active site Lys side chain also involved in H-bonds to the phosphate groups in ATP [7] . These interactions clearly show that insertion of the 3 10 -helix into the catalytic cleft directly blocks ATP binding.
Even in the absence of the 3 10 -helix, however, p27 KIP1 is still capable of inhibiting CDK2. This is a result of the distortion of the catalytic cleft induced by binding of the CKI to the CDK [7] .
Studies with p21 WAF1 -derived synthetic peptides [129, 130] clearly showed that efficient CDK inhibition, as well as inhibition of cell proliferation through cell cycle arrest, could be achieved using the protein-protein interaction between the CKI and cyclin alone. Here the mechanism involves prevention of the macromolecular CDK substrate pRb from binding to the CDK/cyclin complex in such a way as to permit its phosphorylation. The cyclin-binding motif is strongly conserved amongst the CIP/KIP CKIs (refer to Fig. (23) ) proteins. Only p21 WAF1 contains two copies of this motif but the biological significance of this finding remains unclear. Furthermore, it is now clear that other It can thus be concluded that the interactions summarised in Fig. (22) represent a promising starting point for the rational design of selective peptidomimetic small-molecule CDK4/6 inhibitors with potential as novel cancer therapeutics. Further interest in INK4 CKIs as a potential source for the development of cancer therapeutics stems from the fact that e.g. both full-length p16 INK4a , as well as the CDK6-inhibitory peptides derived from it discussed above, have been shown [124] to be able to inhibit α v β 3 integrin-mediated cell spreading, a phenomenon closely associated with tumour-related activities such as neovascularisation and tumour metastasis. proteins known to interact with cyclins do so by using the same binding motif. These proteins include the E2F transcription factors, as well as the pRb-related CDK substrates [131, 132] . An alignment of the appropriate sequence portions is shown in Fig. (26) . Cell-permeable forms of peptides containing this motif have been shown to be able to induce preferentially transformed cells to undergo apoptosis relative to non-transformed cells [133] . The cyclin-binding motif is relevant to cyclin A/CDK2, cyclin E/CDK2, cyclin D/CDK4 but does not appear to be involved in cyclin B/CDK1 complexes.
residues in this helix involved are highly conserved in the cyclin box [134] .
Peptide Library Approaches
Since they contain numerous protein-protein interaction sites whose inhibition with e.g. peptide ligands can potentially lead to inactivation of kinase activity, CDKs represent particularly suitable targets for genetic [135] or chemical [136] peptide library approaches. One such approach, involving peptide aptamers, i.e. random-sequence peptides displayed within the scaffold of a suitable protein, was reported recently [137] . Peptide aptamer strategies are particularly attractive since they permit intra-cellular library deconvolution by two-hybrid genetic engineering methods. A number of aptamers containing 20-residue variable regions inserted in the active site of Escherichia coli thioredoxin were thus shown to bind tightly to CDK2 and to inhibit protein function in vitro. One aptamer inhibited CDK function with distinct substrate specificity for histone H1 over pRb and its expression in mammalian cells retarded progression through G 1 phase. The aptamer was shown to bind at or near the active site of CDK2. More important from a drug design point of view, it was also shown that the aptamer's variable region was sufficient for biological activity [138] . Thus a 20-residue synthetic peptide containing this region inhibited the phosphorylation by CDK2/cyclin E of histone H1 but not of pRb. Inhibition of the histone H1 kinase activity had an IC 50 value of 7 µM. This was ca. 1000-fold higher than inhibition by the The finding that blocking the interaction of substrates with cyclin/CDK complexes is sufficient for CDK inhibition offers a different approach to ATP antagonism for the development of CDKselective cancer therapeutics. The crystal structure of the p27 KIP1 /CDK2/cyclin A complex shows that the interaction of the above cyclin-binding motif involves a groove on the surface of cyclin, formed mainly by two α-helices, see Fig. (27) . The p27 KIP1 binding coil has a rigid conformation. At its N-terminus, it starts with a reverse turn (residues 26 -29), followed by an extended region (residues 29 -31), and ends with another turn, stabilised by an intramolecular H-bond. The first turn and the extended region interact with cyclin A mainly through H-bonds and apolar contacts involving Ala 28 . The second turn binds more deeply into a hydrophobic pocket in the cyclin groove. Multiple van der Waal's contacts are observed mainly to the Leu-Phe pair of p27 KIP1 . The contacts to the α1 helix are particularly significant, because the Fig. (24) . Interactions between p27 KIP1 and CDK2/cyclin A. The complex structure determined at 2.3 Å by X-ray crystallography [128] is shown: the protein backbone of p27 KIP1 , CDK2, and cyclin A are coloured, green, blue, and light green, respectively. The portions of p27 KIP1 making contact with cyclin A and CDK2 are shown in red and magenta, respectively. corresponding thioredoxin aptamer. Clearly in this case the conformational constraint imposed by the scaffold upon the variable region was a prime determinant of potency. remains largely obscure [140] . The crystal structure of a CKS protein in complex with CDK2 was solved recently [141] and the stage is thus set for the rational design of inhibitors of CKS binding. It will be interesting to find out what biological functions such inhibitors possess.
Inhibitors of Other Regulatory ProteinProtein Interaction Sites of CDKs: Future Directions Gene Transfer and Antisense Technologies
Other regulators of CDK activity which are amenable in principle to the development of therapeutic agents include the proteins which regulate the phosphorylation state of CDKs such as CAK, CDC25 phosphatases, as well as the WEE1 and MYT1 kinases [2, 8] . Furthermore, although much is now known about the molecular recognition events leading to partial activation of CDKs by their cyclin partners [139, 7, 107] , inhibition of these events as the basis for drug design has apparently not yet been exploited. CKS proteins are small subunits which are essential components of the CDKs which regulate mitosis. However, the precise function of the CKS proteins Loss of checkpoint control due to defects in key proteins including pRb, p53, p16 INK4a , p21 WAF1 , and p27 KIP1 , is a hallmark of cancer and thus an attractive target for therapeutic intervention [142] . Gene therapy approaches, particularly those utilising replication-defective recombinant adenovirus vectors encoding CKIs, have recently shown some promise [143] . For example, a chimeric p27/p16 tumour suppressor vector gene induced cell growth arrest and apoptosis when overexpressed in certain tumour cell lines, as well as showing therapeutic effect in several in vivo animal tumour models [144] . Various approaches have been applied using antisense oligodeoxynucleotides in order to target CDK activity [1, 2, 143] . The main challenge which continues to face antisense technologies in general concerns the problems of delivering suitable oligodeoxynucleotides to living cells.
CDK INHIBITION AND APOPTOSIS
Most of the inhibitors of CDKs discussed above can arrest proliferating cells at either the G 1 -S and/or the G 2 -M boundaries and are capable under certain circumstances of inducing apoptosis in a Fig. (26) . Cyclin-binding motif in CIP/KIP CKIs, E2Fs, and pRBs. Fig. (27) . Details of the interaction between p27 KIP1 and cyclin A. Residues 205 -301 of cyclin A and residues 25 -37 of p27 KIP1 are shown only. The p27 KIP1 residues making hydrophobic contacts are shown in white, those forming hydrogen bonds in red. The unusual structural element guiding the p27 KIP1 out of the cyclin binding groove and permitting Phe 33 to penetrate deeply into a hydrophobic pocket is shown in yellow. The backbone of the cyclin A residues making van der Waal's or hydrogen bonding contacts with p27 KIP1 are coloured cyan (α1 helix), violet (α3 helix) and orange.
p53-and pRb-independent manner (Ref. [1] , and references cited therein). Due to these properties, CDK inhibitors are particularly attractive therapeutic agents for the treatment of cancers, however, a number of other proliferative diseases involving CDK function are also starting to be addressed with these agents [17] . The apparent ability of certain CDK2 inhibitors selectively to induce apoptosis in tumour cells has been surprising; however, a possible explanation involving inappropriate expression or activity of the transcription factors belonging to the E2F family was recently proposed [139] . The E2F transcription factors are designed to be active during only a narrow window of time during the normal cell cycle: While pRb remains in its normal hypophosphorylated state, it binds E2Fs, preventing them from promoting transcription. Late in the G 1 phase, however, pRb becomes phosphorylated by G 1 cyclin/CDK complexes and the transcription-activating domains of E2Fs are unmasked. This leads to a burst of E2F-activated transcription. Subsequently, progression through S phase is enabled by activation of cyclin A/CDK2 complexes. But these complexes also phosphorylate E2Fs, which causes them to dissociate from DNA. Cessation of E2F-promoted transcription in the cell cycle is then achieved. Experiments with transgenic mice lacking the E2F-1 factor showed [145, 146] that the E2F-1 gene possesses properties of a tumour suppressor and it is now clear that while high levels of E2F-1 favour passage through the G 1 phase [147] , continued and inappropriate E2F-1 transcription-promoting activity triggers apoptosis. Recent data suggests that even minor reduction of the cyclin A/CDK2-mediated shutdown of E2Fs will selectively direct tumour cells, which commonly express higher levels of active E2Fs than normal cells, towards apoptosis [148] .
